Climb Bio (NASDAQ:CLYM) Trading 10.8% Higher - What's Next?

Key Points

• Shares jumped 10.8% on Tuesday to $10.74 (intraday high $11.10) on volume of 964,065 shares, about 42% above the average, with the 50‑day/200‑day moving averages at $7.55 and $4.87 respectively.
• Several analysts have initiated coverage or raised targets (Mizuho, HC Wainwright, Truist, Oppenheimer), leaving a consensus "Buy" rating and an average price target of $17.30.
• Climb Bio remains unprofitable—Q1 EPS was -$0.26 versus an expected -$0.20 and sell‑side forecasts -1.11 EPS for the year—while operating as a clinical‑stage biotech with a market cap of about $548 million.

Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) traded up 10.8% during trading on Tuesday . The company traded as high as $11.10 and last traded at $10.74. 964,065 shares changed hands during trading, an increase of 42% from the average session volume of 676,829 shares. The stock had previously closed at $9.69.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CLYM shares. Mizuho initiated coverage on shares of Climb Bio in a research note on Wednesday, April 15th. They issued an "outperform" rating and a $18.00 price target on the stock. HC Wainwright lifted their price objective on shares of Climb Bio from $11.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, March 10th. Truist Financial initiated coverage on shares of Climb Bio in a report on Tuesday, March 17th. They issued a "buy" rating and a $17.00 price objective for the company. Piper Sandler initiated coverage on shares of Climb Bio in a report on Friday, February 13th. They issued an "overweight" rating for the company. Finally, Oppenheimer lifted their price objective on shares of Climb Bio from $10.00 to $18.00 and gave the company an "outperform" rating in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $17.30.

Climb Bio Trading Up 18.5%

The company has a market cap of $548.39 million, a price-to-earnings ratio of -12.90 and a beta of 0.02. The firm's fifty day simple moving average is $7.55 and its 200 day simple moving average is $4.87.

Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). As a group, sell-side analysts expect that Climb Bio, Inc. will post -1.11 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Climb Bio during the 4th quarter worth approximately $43,000. Blair William & Co. IL acquired a new position in Climb Bio during the 4th quarter worth approximately $44,000. Balyasny Asset Management L.P. acquired a new position in Climb Bio during the 4th quarter worth approximately $57,000. Vanguard Personalized Indexing Management LLC acquired a new position in Climb Bio during the 3rd quarter worth approximately $29,000. Finally, AQR Capital Management LLC acquired a new position in Climb Bio during the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 69.76% of the company's stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.